Apollo Hospitals Q4 FY25 profit jumps 54%, ₹10 dividend

Stock in focus after March-quarter beat

Apollo Hospitals Enterprise shares are expected to be in focus after the company reported a sharp year-on-year rise in profit for the March quarter (Q4 FY25), beating Street estimates. The company reported net profit of ₹390 crore in Q4 FY25, up 53.5% from ₹254 crore in Q4 FY24. Estimates cited in reports were around ₹374 crore to ₹368 crore, implying a clear beat on expectations.

Revenue from operations grew 13% year-on-year to ₹5,592 crore in Q4 FY25, versus ₹4,944 crore in the year-ago quarter. Sequentially, profit after tax (PAT) was reported up 5% from ₹372 crore in Q3 FY25, while revenue rose 1.2% from ₹5,527 crore in the previous quarter.

Key quarterly numbers and margin expansion

The quarter also showed improvement in operating performance. EBITDA was reported at about ₹769.9 crore to ₹770 crore in Q4 FY25, up roughly 20% from ₹640.5 crore in Q4 FY24. EBITDA margin improved to 13.8% in Q4 FY25 from 13% in Q4 FY24, according to the figures cited.

Separately, another set of numbers in the shared data points to Profit Before Tax (PBT) of ₹582.70 crore, up 13.04% quarter-on-quarter from ₹515.50 crore and up 35.51% year-on-year. The same section also cites net profit of ₹432.80 crore, up 11.09% quarter-on-quarter from ₹389.60 crore and up 41.81% year-on-year. These figures differ from the ₹390 crore Q4 FY25 profit cited across multiple lines, indicating that different presentations or definitions may be in play across sources.

Expenses rise alongside scale-up

Total expenses in Q4 FY25 were reported at ₹5,148 crore, up from ₹5,060 crore in Q3 FY25 and ₹4,612 crore in Q4 FY24. The cost increase was attributed to key heads including cost of materials consumed, changes in inventories, employee benefits, and finance costs.

Other income was also noted as supportive, with one data point stating other income more than doubled year-on-year to ₹61.1 crore.

Dividend: ₹10 per share, record date set

Apollo Hospitals’ board recommended a final dividend of ₹10 per equity share for FY25. The record date to determine eligible shareholders has been set for August 19, 2025. One report also states that the dividend, if declared at the annual general meeting, will be paid on or before September 10, 2025.

The dataset also mentions an interim dividend of ₹9 per share that was paid on February 28, and indicates total FY25 dividend of ₹19 per share (final plus interim).

Segment performance: hospitals, AHLL, and HealthCo

Some reports in the shared information provide segment-level details for Q4 FY25. Healthcare Services or the hospital segment revenue rose 10% to ₹2,822 crore. Segment EBITDA rose 16% to ₹686.3 crore, and segment PAT grew 37% to ₹385.2 crore.

Apollo Health and Lifestyle (AHLL) revenue increased 11% to ₹394 crore, while loss narrowed to ₹4.3 crore. Apollo HealthCo (Digital and Pharmacy) revenue rose 17% to ₹2,376.3 crore with profit of ₹8.8 crore.

Full-year FY25 snapshot and scale milestone

For the full year, consolidated revenue from operations is cited at ₹21,794 crore, up 14% year-on-year. Full-year EBITDA is reported at ₹3,021.9 crore, up 26%, while net profit rose about 61% to around ₹1,446 crore (also cited as ₹1,445.90 crore).

Another data point notes the company crossed consolidated revenue exceeding ₹20,000 crore in FY25. It also states Healthcare Services revenue surpassed ₹10,000 crore during the year.

Expansion: plan to add 4,300 beds

Apollo Hospitals is also linked to an expansion plan. The shared text states the company plans to add 4,300 beds over the next 3 to 4 years. While the underlying capex and location details are not included in the provided material, the stated bed addition indicates a multi-year capacity buildout.

Results at a glance

Timeline and key dates

Market impact: why the quarter matters

The quarter combined strong profit growth with modest sequential improvement in revenue, suggesting operational momentum into the end of FY25. The beat versus Street estimates on net profit was a key headline, alongside margin improvement at the EBITDA level to 13.8%.

At the same time, the rise in total expenses to ₹5,148 crore shows that growth came alongside higher operating costs. Investors are also likely to track how investments, including those referenced around Apollo 24/7, influence margins over coming quarters, given that segment data indicates profitability in HealthCo and narrowing losses in AHLL.

Analysis: dividend clarity and expansion signals

The final dividend recommendation of ₹10 per share, with a clearly stated record date of August 19, 2025, provides visibility on shareholder payouts. The references to an interim dividend of ₹9 per share also indicate that FY25 payouts are being positioned as a two-part distribution.

The plan to add 4,300 beds over 3 to 4 years is a material capacity signal for a hospital-led business. Combined with FY25 revenue of ₹21,794 crore and full-year EBITDA of ₹3,021.9 crore, the numbers reinforce the scale at which Apollo is operating, while keeping attention on execution and cost control.

Conclusion

Apollo Hospitals closed Q4 FY25 with net profit of ₹390 crore on revenue of ₹5,592 crore, alongside a ₹10 per share final dividend recommendation and record date set for August 19, 2025. The next key milestones for investors are dividend eligibility timelines and any further updates on the 4,300-bed expansion plan over the coming years.